The Journal of Clinical Investigation (Nov 2022)

RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer

  • Peng Deng,
  • Zining Wang,
  • Jinghong Chen,
  • Shini Liu,
  • Xiaosai Yao,
  • Shaoyan Liu,
  • Lizhen Liu,
  • Zhaoliang Yu,
  • Yulin Huang,
  • Zhongtang Xiong,
  • Rong Xiao,
  • Jiuping Gao,
  • Weiting Liang,
  • Jieping Chen,
  • Hui Liu,
  • Jing Han Hong,
  • Jason Yongsheng Chan,
  • Peiyong Guan,
  • Jianfeng Chen,
  • Yali Wang,
  • Jiaxin Yin,
  • Jundong Li,
  • Min Zheng,
  • Chao Zhang,
  • Penghui Zhou,
  • Tiebang Kang,
  • Bin Tean Teh,
  • Qiang Yu,
  • Zhixiang Zuo,
  • Qingping Jiang,
  • Jihong Liu,
  • Ying Xiong,
  • Xiaojun Xia,
  • Jing Tan

Journal volume & issue
Vol. 132, no. 22

Abstract

Read online

Prevalent copy number alteration is the most prominent genetic characteristic associated with ovarian cancer (OV) development, but its role in immune evasion has not been fully elucidated. In this study, we identified RAD21, a key component of the cohesin complex, as a frequently amplified oncogene that could modulate immune response in OV. Through interrogating the RAD21-regulated transcriptional program, we found that RAD21 directly interacts with YAP/TEAD4 transcriptional corepressors and recruits the NuRD complex to suppress interferon (IFN) signaling. In multiple clinical cohorts, RAD21 overexpression is inversely correlated with IFN signature gene expression in OV. We further demonstrated in murine syngeneic tumor models that RAD21 ablation potentiated anti–PD-1 efficacy with increased intratumoral CD8+ T cell effector activity. Our study identifies a RAD21–YAP/TEAD4–NuRD corepressor complex in immune modulation, and thus provides a potential target and biomarker for precision immunotherapy in OV.

Keywords